Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report)’s stock price fell 7.5% on Wednesday . The stock traded as low as $4.90 and last traded at $4.90. 1,174 shares changed hands during trading, a decline of 85% from the average session volume of 7,832 shares. The stock had previously closed at $5.30.
Pasithea Therapeutics Price Performance
The company has a 50-day moving average of $6.22 and a 200-day moving average of $6.91.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($3.70) earnings per share for the quarter.
Pasithea Therapeutics Company Profile
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Read More
- Five stocks we like better than Pasithea Therapeutics
- Overbought Stocks Explained: Should You Trade Them?
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What is the FTSE 100 index?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Do ETFs Pay Dividends? What You Need to Know
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
